Savara (SVRA) Long-Term Debt Issuances (2016 - 2025)
Savara (SVRA) posted quarterly Long-Term Debt Issuances of $29.6 million for Q1 2025, up 5658.37% quarter-over-quarter from $514000.0 in Q1 2020.
Powered by 
Analysis
Savara (SVRA) Long-Term Debt Issuances (2016 - 2025) Analysis & Trends
Savara (SVRA) has reported Long-Term Debt Issuances for 3 consecutive years, with $29.6 million the latest figure, recorded in Q1 2025.
- In Q1 2025, Long-Term Debt Issuances changed N/A year-over-year to $29.6 million; the TTM figure through Dec 2025 stood at $29.6 million (changed N/A YoY), while the FY2025 annual figure was $29.6 million, changed N/A from the prior year.
- Long-Term Debt Issuances improved to $29.6 million in Q1 2025 per SVRA's latest filing, from $514000.0 in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $29.6 million in Q1 2025 and bottomed at $29.6 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Savara | 1.36 Bn | 1.36 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | 29.60 Mn |
| Mar 31, 2020 | 514,000.00 |
| Dec 31, 2016 | 100,000.00 |